Image: Publications Office of the European Union | Public domain | via Wikimedia Commons
Barbara Boehringer is an heir to the Boehringer Ingelheim fortune, best known as the world's largest privately-owned pharmaceutical company. As of February 2026, her estimated net worth is $5.9 billion. The German company was founded in 1885. The company has grown into a global enterprise with 53,000 employees in 130 markets. Some of the company's most famous drugs now treat COPD, anti-coagulation, and type 2 diabetes.
Barbara Boehringer is part of the Boehringer family, which founded Boehringer Ingelheim in 1885 in Ingelheim am Rhein, Germany. The company began with 28 employees and focused on producing ingredients for pharmacies.
Boehringer Ingelheim has grown to become the world's largest privately-owned pharmaceutical company. The company's key areas of interest are respiratory diseases, metabolism, immunology, oncology, and diseases of the central nervous system. Barbara Boehringer's wealth stems from this family business.
The company's main focus is on research and development of innovative healthcare products. In January 2026, Boehringer Ingelheim partnered with Simcere to advance a dual-target antibody treatment for inflammatory bowel disease.
While specific philanthropic amounts are unavailable, Boehringer Ingelheim is committed to sustainable development and has values that guide their actions.
Teamwork is at the heart of our success.
We need people with the courage to speak out when they see something wrong.
We live in a fast-moving world.
Innovation is our lifeblood.
We are driven to excel.
